| CAS NO: | 1370261-97-4 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 2mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 429.91 |
|---|---|
| Formula | C19H23N9O.HCl |
| CAS No. | 1370261-97-4 (HCl); |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 86 mg/mL (200.0 mM) |
| Water: <1 mg/mL | |
| Ethanol: 86 mg/mL (200.0 mM) | |
| Solubility (In vivo) | Saline: 30 mg/mL |
| Synonyms | P505-15; P-50515; PRT2607; PRT062607; P50515; BIIB057; PRT-062607; PRT 062607; PRT-2607; PRT 2607; P-505-15; P 505-15; P 50515; BIIB-057; BIIB 057. Chemical Name: 4-((3-(2H-1,2,3-triazol-2-yl)phenyl)amino)-2-(((1R,2S)-2-aminocyclohexyl)amino)pyrimidine-5-carboxamide hydrochloride SMILES Code: O=C(C1=CN=C(N[C@H]2[C@@H](N)CCCC2)N=C1NC3=CC=CC(N4N=CC=N4)=C3)N.[H]Cl |
| In Vitro | In vitro activity: PRT062607(P505-15) anti-SYK activity is at least 80-fold greater than its affinity for other kinases. at least 80-fold greater than its affinity for other kinases. PRT062607 potently inhibits B cell antigen receptor-mediated B cell signaling and activation (IC50 0.27 and 0.28 μM, respectively) and Fcε receptor 1-mediated basophil degranulation (IC50 0.15 μM). PRT062607 inhibits BCR-dependent secretion of the chemokines CCL3 and CCL4 by CLL cells, and leukemia cell migration toward the tissue homing chemokines CXCL12, CXCL13, and beneath stromal cells. PRT062607 furthermore inhibits Syk and extracellular signal-regulated kinase phosphorylation after BCR triggering Kinase Assay: The extent of substrate phosphorylation by Syk is measured in the presence of various PRT062607 concentrations. Syk activity is determined by a fluorescent antibody specific for phosphorylated tyrosine by using the increase of FRET. Twelve concentrations are tested for dose response. Specificity and potency of kinase inhibition is determined by evaluation of PRT062607 in the Millipore KinaseProfiler panel of 270 independent purified kinase assays. For profiling, PRT062607 is tested in duplicate at two concentrations at a fixed concentration of ATP. Subsequently, IC50 determinations using the radioactive assays are carried out at an ATP concentration optimized for each individual kinase. All radioactive ATP incorporation enzyme assays are performed at Millipore. Cell Assay: To compare the relative sensitivity of primary versus tumor B-cells, the mixing experiments in which SU-DHL6 was combined with human whole blood and treated with P505-15 were performed. Under these conditions, whereas the tumor B-cell line underwent apoptosis in response to SYK inhibition, primary B-cells did not. |
|---|---|
| In Vivo | The pharmacokinetic/pharmacodynamic relationship predicted that 70% Syk suppression is maintained in mice over a 24h period after 30 mg/kg dosing. At 15 mg/kg, Syk inhibition ranges from 7.5% (Cmin) to 78.4% (Cmax) with an average inhibition of 67% over 24 h. Oral administration of PRT062607 produced dose-dependent anti-inflammatory activity in two rodent models of rheumatoid arthritis. Statistically significant efficacy is observed at concentrations that specifically suppressed Syk activity by 67% |
| Animal model | NOD/SCID mice injected with Ramos cells |
| Formulation & Dosage | 10, 15, or 20 mg/kg; Oral administration |
| References | J Pharmacol Exp Ther. 2012 Feb;340(2):350-9; Leukemia. 2012 Jul;26(7):1576-83. |
P505-15 selectively inhibits proliferation of Syk-dependent B cell lines. J Pharmacol Exp Ther.2012 Feb;340(2):350-9. |
P505-15 attenuates antibody-induced inflammation in a mouse model of rheumatoid arthritis. J Pharmacol Exp Ther.2012 Feb;340(2):350-9. |
Oral administration of P505-15 significantly ameliorates the severity and development of arthritis in the rat CIA model. J Pharmacol Exp Ther. 2012 Feb;340(2):350-9. |
m.cnreagent.com
